Detalhe da pesquisa
1.
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Blood
; 139(3): 384-398, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34232979
2.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32693406
3.
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Blood
; 133(22): 2401-2412, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975638
4.
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.
Haematologica
; 103(6): 1065-1072, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29191842
5.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Blood Cancer Discov
; 5(3): 146-152, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441243
6.
G-protein coupled receptor (GPCR) mutations in lymphoid malignancies: linking immune signaling activation and genetic abnormalities.
Haematologica
; 103(8): 1252-1255, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30065018
7.
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Nat Commun
; 14(1): 5825, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37730678
8.
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.
Br J Haematol
; 158(6): 712-26, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22816737
9.
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.
Sci Adv
; 8(3): eabl4644, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35044826
10.
CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.
Blood Adv
; 4(5): 893-905, 2020 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32150608
11.
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
J Med Chem
; 61(15): 6546-6573, 2018 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29890830
12.
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
J Med Chem
; 61(15): 6518-6545, 2018 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29953809
13.
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Cancer Res
; 65(8): 3264-72, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15833859
14.
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
Nat Commun
; 8: 15424, 2017 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548080
15.
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Oncotarget
; 7(25): 37407-37419, 2016 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27270648
16.
Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis.
Cell Cycle
; 13(11): 1717-26, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24675889
17.
Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
Nat Commun
; 5: 3904, 2014 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24887457
18.
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Cancer Cell
; 22(6): 812-24, 2012 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23238016
19.
Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas.
PLoS One
; 6(9): e24939, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21957467
20.
MALT lymphoma meets stem cells.
Cell Cycle
; 11(16): 2961-2, 2012 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22825253